Esper Boel

Esper Boel is a Board Member at MonTa Biosciences. Prior to this, they were with ResoTher Pharma ApS, and before that, they were with MonTa Biosciences. They began their career in 1979 as Corporate Vice President, CVP, and Head of Biotechnology at Novo Nordisk, where they were responsible for fully integrating and building a world-class, international biotechnology unit focused on early research and discovery of new therapeutic proteins. Some of the major protein classes addressed were growth hormone, coagulation factors and monoclonal antibodies; and from all classes, several candidates have entered clinical development within growth hormone disorders, bleeding disorders, autoimmune inflammation and cancer.

Esper Boel earned their Ph.D. in molecular biology from Aarhus University.